367 related articles for article (PubMed ID: 33340527)
21. Revolutionizing technologies of nanomicelles for combinatorial anticancer drug delivery.
Jo MJ; Jin IS; Park CW; Hwang BY; Chung YB; Kim JS; Shin DH
Arch Pharm Res; 2020 Jan; 43(1):100-109. PubMed ID: 31989478
[TBL] [Abstract][Full Text] [Related]
22. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
Xi QP; Pu DH; Lu WN
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy.
Li Y; Gao Y; Zhang X; Guo H; Gao H
Int J Pharm; 2020 Dec; 591():119986. PubMed ID: 33069895
[TBL] [Abstract][Full Text] [Related]
24. Extremely long tumor retention, multi-responsive boronate crosslinked micelles with superior therapeutic efficacy for ovarian cancer.
Xiao W; Suby N; Xiao K; Lin TY; Al Awwad N; Lam KS; Li Y
J Control Release; 2017 Oct; 264():169-179. PubMed ID: 28847739
[TBL] [Abstract][Full Text] [Related]
25. Rapid and soft formulation of folate-functionalized nanoparticles for the targeted delivery of tripentone in ovarian carcinoma.
Tomasina J; Poulain L; Abeilard E; Giffard F; Brotin E; Carduner L; Carreiras F; Gauduchon P; Rault S; Malzert-Fréon A
Int J Pharm; 2013 Dec; 458(1):197-207. PubMed ID: 24084450
[TBL] [Abstract][Full Text] [Related]
26. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
27. The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer.
Jia LT; Zhang YC; Li J; Tian Y; Li JF
Clin Transl Oncol; 2016 Mar; 18(3):233-9. PubMed ID: 26220095
[TBL] [Abstract][Full Text] [Related]
28. Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer.
Parker JP; Ude Z; Marmion CJ
Metallomics; 2016 Jan; 8(1):43-60. PubMed ID: 26567482
[TBL] [Abstract][Full Text] [Related]
29. An Update on Biomedical Application of Nanotechnology for Alzheimer's Disease Diagnosis and Therapy.
Panahi Y; Mohammadhosseini M; Abadi AJ; Akbarzadeh A; Mellatyar H
Drug Res (Stuttg); 2016 Nov; 66(11):580-586. PubMed ID: 27701713
[TBL] [Abstract][Full Text] [Related]
30. Cancer Nanotechnology-An Excursion on Drug Delivery Systems.
Sharma M; Pandey C; Sharma N; Kamal MA; Sayeed U; Akhtar S
Anticancer Agents Med Chem; 2018; 18(15):2078-2092. PubMed ID: 30033877
[TBL] [Abstract][Full Text] [Related]
31. Nanocarriers for anticancer drugs--new trends in nanomedicine.
Drbohlavova J; Chomoucka J; Adam V; Ryvolova M; Eckschlager T; Hubalek J; Kizek R
Curr Drug Metab; 2013 Jun; 14(5):547-64. PubMed ID: 23687925
[TBL] [Abstract][Full Text] [Related]
32. Targeted nanoparticulate drug-delivery systems for treatment of solid tumors: a review.
Bhattacharjee H; Balabathula P; Wood GC
Ther Deliv; 2010 Nov; 1(5):713-34. PubMed ID: 22833959
[TBL] [Abstract][Full Text] [Related]
33. Nanoparticles for tumor-specific intracellular drug delivery.
Yeo Y; Xu P
Annu Int Conf IEEE Eng Med Biol Soc; 2009; 2009():2403-5. PubMed ID: 19964955
[TBL] [Abstract][Full Text] [Related]
34. Nano-pharmaceutical formulations for targeted drug delivery against HER2 in breast cancer.
Sadat SM; Saeidnia S; Nazarali AJ; Haddadi A
Curr Cancer Drug Targets; 2015; 15(1):71-86. PubMed ID: 25564255
[TBL] [Abstract][Full Text] [Related]
35. Management of retinoblastoma: opportunities and challenges.
Bhavsar D; Subramanian K; Sethuraman S; Krishnan UM
Drug Deliv; 2016 Sep; 23(7):2488-2496. PubMed ID: 25758593
[TBL] [Abstract][Full Text] [Related]
36. Role of Nanobiotechnology in Drug Delivery.
Jain KK
Methods Mol Biol; 2020; 2059():55-73. PubMed ID: 31435915
[TBL] [Abstract][Full Text] [Related]
37. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
[TBL] [Abstract][Full Text] [Related]
38. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E
Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
[TBL] [Abstract][Full Text] [Related]
39. Colorectal Cancer Management by Herbal Drug-Based Nanocarriers: An Overview.
Kulwal V; Baxi K; Sawarkar SP; Bhatt LK
Crit Rev Ther Drug Carrier Syst; 2020; 37(1):65-104. PubMed ID: 32450014
[TBL] [Abstract][Full Text] [Related]
40. Drug delivery approaches for breast cancer.
Singh SK; Singh S; Lillard JW; Singh R
Int J Nanomedicine; 2017; 12():6205-6218. PubMed ID: 28883730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
